- Home
- TVGN vs DSGN Comparison
TVGN vs DSGN Comparison
Compare TVGN & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVGN
- DSGN
- Stock Information
- Founded
- TVGN 2020
- DSGN 2017
- Country
- TVGN United States
- DSGN United States
- Employees
- TVGN N/A
- DSGN N/A
- Industry
- TVGN Blank Checks
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- TVGN Finance
- DSGN Health Care
- Exchange
- TVGN Nasdaq
- DSGN Nasdaq
- Market Cap
- TVGN 193.1M
- DSGN 224.8M
- IPO Year
- TVGN N/A
- DSGN 2021
- Fundamental
- Price
- TVGN $1.28
- DSGN $4.02
- Analyst Decision
- TVGN Strong Buy
- DSGN Hold
- Analyst Count
- TVGN 1
- DSGN 1
- Target Price
- TVGN $10.00
- DSGN $4.00
- AVG Volume (30 Days)
- TVGN 675.8K
- DSGN 91.9K
- Earning Date
- TVGN 06-10-2025
- DSGN 05-07-2025
- Dividend Yield
- TVGN N/A
- DSGN N/A
- EPS Growth
- TVGN N/A
- DSGN N/A
- EPS
- TVGN N/A
- DSGN N/A
- Revenue
- TVGN N/A
- DSGN N/A
- Revenue This Year
- TVGN N/A
- DSGN N/A
- Revenue Next Year
- TVGN N/A
- DSGN N/A
- P/E Ratio
- TVGN N/A
- DSGN N/A
- Revenue Growth
- TVGN N/A
- DSGN N/A
- 52 Week Low
- TVGN $0.26
- DSGN $2.60
- 52 Week High
- TVGN $3.09
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- TVGN 58.67
- DSGN 53.86
- Support Level
- TVGN $1.15
- DSGN $3.67
- Resistance Level
- TVGN $1.40
- DSGN $4.13
- Average True Range (ATR)
- TVGN 0.09
- DSGN 0.30
- MACD
- TVGN 0.01
- DSGN 0.05
- Stochastic Oscillator
- TVGN 56.25
- DSGN 85.78
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.